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ABSTRACT 
Objective: Oral drug delivery is the most desired route for drug administration for its well-known features. Therefore, many attempts were 
implemented to improve the poor solubility of many active ingredients in order to enhance their dissolution and absorption via the oral route. From 
these, the liquisolid system is a very promising technology for enhancing solubility and bioavailability of poorly soluble drugs. 
Methods: In this research, oral capsules of cefixime were prepared by liquisolid technique after mixing different concentrations of the drug with 
propylene glycol (non-volatile solvent), followed by their addition to different proportions of microcrystalline cellulose and aerosil i.e. different 
carrier: coating (R-value). The liquisolid capsules were evaluated for In vitro disintegration and dissolution in addition to content uniformity and 
weight variations. Furthermore, solubility studies, scanning electron microscope (SEM) were performed to the optimum formula. Finally, the 
release profile of the optimum formula was compared with the marketed cefixime capsules. 
Results: Liquisolid formula (F3) with 70% cefixime and R-value equals 10 was selected as the optimum formula having higher % release in 45 min 
(99.5%±0.53) compared to other formulas with faster release rate in the first 20 min than marketed capsules. It had an acceptable disintegration 
time (25 min±0.76), content uniformity (197.6±0.92) and weight variation (698.04±0.16). Results of solubility study, SEM assured enhancement in 
solubility and dispersibility of the drug.  
Conclusion: This research proved that liquisolid system is a promising technology in improving the solubility and dissolution of cefixime from its 
capsules and hence it may improve its absorption and oral bioavailability. 
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Despite of plenty of different routes for administrating a drug, yet 
oral route solely remains the preferred one, simply because of its 
convenience, optimum patient compliance as well as low costs of 
production. However, for a scientist to formulate a drug into, any 
oral dosage form, a drug must possess sufficient water solubility, 
therefore, it is quite challenging to formulate any drug in oral dosage 
form since nearly half of the active substances being identified are 
either insoluble or poorly soluble in water. The poor dissolution 
rates of water-insoluble or poorly soluble drugs are significant 
problem confronting the pharmaceutical industry as it is considered 
the rate limiting step for absorption and hence for bioavailability. 
Different methods are employed to improve the dissolution 
characteristics of poorly water-soluble drugs like pH adjustment, 
cosolvents solubilisation, microemulsion, polymeric modification, 
solid dispersion, drug complexation, micronization, self-
emulsification, use of a surfactant as a solubilizing agent, 
lyophilisation, the pro-drug approach, microencapsulation and 
inclusion of drug solutions into soft gelatin capsules. Recently, better 
approaches are available to prepare the liquid oily medications, and 
drug solutions of water-insoluble solid drugs and the most 
promising one is the use of the liquisolid system or powder solution 
technology [1-6]. 
Liquisolid system is a novel technique developed by Spireas et al., it 
is a powdered form of liquid drug formulated by dissolving or 
dispersing the slightly soluble drug in an appropriate non-volatile 
solvent like polyethylene glycol (PEG) 200 or 400, propylene glycol 
(PG) or tween 80, that is absorbed or adsorbed into and onto the 
carrier like microcrystalline cellulose (MCC) PH 101 or 102 followed 
by its adsorption onto the surface of suitable coating material like 
aerosil 200. Hence, the increased surface area of the drug in powder 
form, enhanced wettability and enhanced dissolution might improve 
the bioavailability of the drug in the body. This technique was 
effectively applied to low dose water-insoluble drugs. On the other 
hand formulation of the high dose was impractical because of the 
high levels of carrier and coating materials that should be added and 
in turn will increase the weight of each tablet above 1 g which is 
very difficult to swallow. Therefore, to overcome this limitation, 
some hydrophilic materials can be added to the liquid medication 
like polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose or 
PEG 35000 which produce dry powder formulations containing a 
liquid with a high concentration of drug using a lower amount of the 
carrier and coating materials [7-12]. 
Cefixime is slightly soluble powder with a low bioavailability when 
given orally (22-54%), belongs to the third-generation 
cephalosporin antibacterial and is given at 200 and 400 mg orally in 
the treatment of susceptible infections, including gonorrhea, otitis 
media, pharyngitis, lower-respiratory-tract infections such as 
bronchitis, and urinary tract infections [13, 14]. 
In this study; liquisolid technique was applied to enhance the 
solubility of cefixime trihydrate using different concentrations of the 
drug in the non-volatile solvent and different ratios of the carrier 
and coating materials in an attempt to improve the drug dissolution 
in comparison to the commercial capsule and hence its oral 
bioavailability as well as reducing its effective dose. 
MATERIALS AND METHODS 
Materials 
Cefixime trihydrate (Lupi Medico, India), MCC PH 102, aerosil 200 
(Samara, Iraq), PG (Samara, Iraq), PVP (Samara, Iraq), marketed 
cefixime 200 mg capsule (Ritemed, Japan). All other chemicals, 
reagents and solutions used were of analytical grade. 
Mathematical modeling for the preparation of the liquisolid 
system  
A mathematical model was employed to accomplish the formulation 
design of the liquisolid system; such model was described by Spireas 
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et al. In this study, PG was used as a liquid vehicle; MCC PH 102 and 
aerosil 200 were used as the carrier and coating materials, 
respectively. The concentration of the drug in PG was taken as 70, 
75, and 80 g% and the carrier: coat ratios (R) used were 6, 8 and 10. 
According to new theories, the carrier and coating powder materials 
can retain only certain amounts of liquid while maintaining 
acceptable flowability and compressibility.  
The weight of carrier powder (Q) in the system was obtained after 
calculating the weight of liquid medication (W) for each 
concentration and after obtaining liquid load factors Lf of the 
formulations for each R ratio used by the application of the following 
equations:  
Lf = Φ+Φ (1/R) …………………. (1) 
Lf = W/Q…………………………… (2) 
Where, Φ and Φ are the flowable liquid retention potential (Φ value) 
of powder excipients which is defined as the maximum weight of 
liquid that can be retained per unit powder material in order to 
produce and acceptably flowing liquid/powder admixture. 
After that the amount of the coating material (q) in each formula 
was calculated as follows:  
R = Q/q………………………. (3) 
By using the above mathematical model, liquisolid mixtures were 
formulated (table 1) first by preparation the liquid medication after 
dissolving the 200 mg cefixime in PG at 80 °C in shaking water bath 
for 15 min, followed by the addition of 10% PVP prior to its mixing 
with the carrier and the coating material using the standard mixing 
process mentioned by spireas [15-17] by one rotation per second in 
three mixing steps. The first step involved uniform mixing for about 
one min to ensure uniform distribution of the liquid medication into 
the powder, followed by evenly distributing it as a uniform layer on 
the surface of the mortar and leaving it for about 5 min to allow the 
drug solution to be incorporated into and onto the powder. The 
third step involved the addition of 4% CCS as a super disintegrant 
that was mixed for another 30 s using the same standard mixing 
process.  
The liquisolid mixtures were incorporated after that into capsules 
by dipping technique to be evaluated. 
 
Table 1: Content of the prepared formulas containing liquisolid cefixime 
Formula % of drug (w/w) R Lf W (mg) Q (mg) Q (mg) Total weight (mg) 
F1 70% 6 0.71 285.7 200.7 33.4 601.7 
F2 70% 8 0.57 285.7 249.3 31.1 655.2 
F3 70% 10 0.49 285.7 290.9 29 701 
F4 75% 6 0.71 266.6 187.3 31.2 561.6 
F5 75% 8 0.57 266.6 232.6 29 611.6 
F6 75% 10 0.49 266.6 271.5 27.1 654.33 
F7 80% 6 0.71 250 175.6 29.2 526.5 
F8 80% 8 0.57 250 218.1 27.2 573.3 
F9 80% 10 0.49 250 254.5 25.4 613.4 
*Abbreviations: Carrier: coating ratio (R), loading factor (Lf
 
Evaluation of the liquisolid powder mixture  
Flowability assessment of the liquisolid powder 
The flow properties of liquisolid formulations were studied by an 
angle of repose, Carr’s index and Hausner’s ratios. All studies were 
done in triplicate, where, the angle of repose was calculated by a 
fixed height cone method, while Carr’s index and Hausner’s ratios 
were measured using bulk and tapped densities [18, 19].  
Solubility study 
The saturated solubility of pure cefixime and optimum liquisolid 
formula (F3) were studied in distilled water and 7.4 phosphate 
buffer. An excess amount of each powder was added to each solution 
and sonicated at room temperature for 1 h, followed by mixing for 
24 h at 25±0.1 °C. The samples were filtered and evaluated by a UV-
spectrophotometer at 288 nm [20].  
Scanning electron microscope (SEM) 
The morphological behaviour of the drug alone and the liquisolid 
system of the optimum formula (F3) was detected by SEM (S-50 
model, FEI company-Netherland), where the complete dis-
appearance of the crystals in the liquisolid mixture assures complete 
solubility of the drug [21, 22].  
Fourier transform infrared spectroscopy (FT-IR) 
The possible interaction of all excipient along with the drug was 
assessed for the optimum formula (F3) using FTIR from 4000-400 
cm
), weight of liquid medication (W), weight of carrier (Q), weight of coating material (q). 
-1
It’s done by individually weighing 20 capsules and the average 
weight is determined. If 2 capsules fall outside the range of 10%, 
then should take another 20 capsules. So the test requirement is met 
if 6 capsules fall outside the 10% range and none of the 6 capsules 
outside 25% range. 
Content uniformity 
It’s performed by and dissolving 10 capsules individually in 7.2 
phosphate buffer followed by measuring the amount of cefixime in 
each capsule by UV-spectrophotometer at 288 nm, the capsules met 
the requirements if only one falls outside±15% but not 
outside±25%. If more than two were in that range, then take 20 
capsules that is assayed individually, they passed the test, if only 3 of 
the 30 capsules was outside the range±15% but not outside±25%. 
Disintegration test 
Disintegration time (DT) was measured to the prepared liquisolid 
capsules in pH 7.2 phosphate buffer at 37±0.5 °C by placing 6 
capsules individually in each tube of the apparatus [24]. 
Dissolution test  
The test was performed using USP type I apparatus (100 rpm) at 
37±0.5 °C, by placing 3 capsules individually in 1000 ml pH 7.2 
phosphate buffer for 45 min. Samples were periodically withdrawn 
and analyzed spectrophotometrically at 288 nm and the % drug 
release after 45 min (% D
 by using the pressed-disk technique [23]. 
Evaluation of the liquisolid capsules 
Weight variation  
45 min
Results of the angle of repose, Carr’s index and Hausner’s ratio with 
the corresponding type of flow are illustrated in table 2. According 
to the USP the results clearly demonstrate that all cefixime liquisolid 
powder had an acceptable flowability. 
) was calculated [25]. 
Statistical analysis 
All the results were statistically analyzed using (ANOVA) single 
factor to compare and assess the significance of the results, where 
(P<0.05) considered to be significant. 
RESULTS AND DISCUSSION 
Flowability parameters of the liquisolid powder  
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Table 2: Flowability parameters of cefixime liquisolid powder with their corresponding type of flow 
Formula Angle of repose Carr’s index Hausner’s ratio Type of flow 
F1 31.3±0.32 15.81±0.96 1.16±0.25 Good 
F2 32.1±0.65 14.32±0.66 1.17±0.21 Good 
F3 30.2±0.95 9.13±0.93 1.1±0.94 Excellent 
F4 29.9±0.76 9.41±0.9 1.11±0.83 Excellent 
F5 32.5±1.04 14.42±0.71 1.18±0.53 Good 
F6 31±0.34 13.91±0.59 1.15±0.68 Good 
F7 29.8±0.76 9.45±0.55 1.11±0.29 Excellent 
F8 32±0.09 14.41±0.35 1.18±0.19 Good 




Results are expressed as mean±SD, n=3. 
The results of the solubility study are illustrated in table 3. The data 
clearly show a significant improvement in the solubility of cefixime 
after its formulation as a liquisolid powder from sparingly soluble to 
freely soluble drug, which might be attributed to the increment in 
surface area and wettability of drug in liquisolid formula F3 in 
comparison to cefixime powder [26]. 
 
Table 3: Solubility data for the cefixime and optimum formula (F3) expressed in g/l 
 Cefixime powder F3 
pH 7.2 phosphate buffer 0.029±0.93 0.375±0.29 
Distilled water 0.027±0.77 0.361±0.33 
*
 
Scanning electron microscope (SEM) study 
Results are expressed as mean±SD, n=3. 
Fig. 1 clearly assures the conversion of cefixime trihydrate by 
liquisolid technique from a crystalline form (A) to the amorphous 
state (B), which proved the complete solubilization or dispersion of 
the drug in the liquisolid system that enhances the dissolution of the 
cefixime from the liquisolid formulas [27]. 
 
 
-A-      -B- 
Fig. 1: SEM image for (A) cefixime trihydrate powder (B) optimum liquisolid formula (F3) containing cefixime trihydrate 
 
 
Fig. 2: FT-IR spectrum of cefixime trihydrate 
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Fig. 3: FT-IR spectrum of optimum liquisolid formula (F3) 
 
Fourier transform infra-red spectroscopy (FT-IR) study 
FT-IR spectrum of cefixime trihydrate and optimum formula (F3) 
were shown in fig. 2 and 3 respectively. Fig. 1 clearly demonstrates 
the characteristic peaks of the drug at 3525 cm-1 which results from 
OH stretching vibration, peaks at 3172 and 2944 cm-1 resulting from 
NH stretching vibration of 1 ° and 2 ° amine, while the stretching 
vibration of C=O of ketone, carboxyl and lactam was clearly 
demonstrated at the bands from 1870-1540 cm-1
Weight variations and content uniformity data  
. On the other hand, 
a little shifting was observed in the peaks the optimum liquisolid 
formula (F3) to a lower frequency might be explained by the H-bond 
formation which might be responsible for solubility enhancement of 
cefixime in the liquisolid system [28, 29]. 
Table 4 demonstrated the weight variation and content uniformity 
of cefixime liquisolid preparation, the result clearly shows that all 
formulas complied with the USP specifications, which suggests a 
uniform distribution of the active ingredients and formulas within 
the capsule dosage form. 
  
Table 4: Weight variations and content uniformity parameters for cefixime liquisolid capsules (mg) 
Formulas Weight variation Content uniformity 
F1 595.4±0.86 195.2±0.54 
F2 645.8±0.56 196.5±0.94 
F3 698.04±0.16 197.6±0.92 
F4 556.32±0.65 196.53±0.65 
F5 603.4±0.72 197.4±0.45 
F6 651.63±0.43 195.8±0.83 
F7 522.3±0.54 197.04±0.17 
F8 568.34±0.23 198.34±0.84 
F9 609.52±0.95 197.05±0.67 
*
 
In vitro disintegration and dissolution test  
Results of In vitro disintegration and dissolution, in addition to the 
dissolution profiles for cefixime liquisolid formulas are illustrated in 
table 5 and fig. (4-6). The results clearly show that disintegration 
time for all formulas was less than 30 min with no significant 
differences between formulas.  
While, the dissolution results demonstrated a significant increment 
in %D
Results are expressed as mean±SD, n=3. 
45 min upon increasing carrier/coat ratio (R) from 6 to 10 in the 
formulas (F1-F3), (F4-F6) and (F7-F9), which might be attributed to 
enhanced wicking, deaggregation and disintegration properties that 
resulted from low liquid/powder ratio, high amount of cellulose and 
low amount of silica (aerosil) which accompanies higher R values. On 
the other hand, the data revealed a significant reduction in % D45 min 
upon increasing % drug from 70% to 80% in formulas (F1-F3), (F4-
F6) and (F7-F9) due to the possible precipitation of the drug on 
aerosil pores at higher concentration, or might be due to the reduced 
amount of solubilized drug resulting from the lesser amount of 
solvent used in higher drug concentration. 
Therefore, F3 with higher R value and lower % of the drug was 
selected as the optimum formula having % D45 min
Furthermore, the comparative release profile of the optimum 
liquisolid formula (F3) and the marketed cefixime capsule (200 mg) 
is illustrated in fig. 7. The fig. shows no significant differences in % 
D
 equals to 
99.5%±0.53.  
45 min, although, a significant differences were observed in the first 
20 min with a greater release rate for F3, which can be explained 
according to the ‘‘Noyes–Whitney” equation and the ‘‘diffusion layer 
model” dissolution theories where the dissolution rate of a drug 
(DR) is equal to. 
DR= (D/h) S (Cs-C) 
Since both D (diffusion coefficient of the drug molecules transported 
through it) and h (thickness of the stagnant diffusion layer formed 
by the dissolving liquid around the drug particles) were constants, 
then DR directly proportional to the S (surface area of the drug 
available for dissolution) and Cs
For this reason, dissolution rate increased in liquisolid systems as it 
contains a solution of the drug in a suitable solvent (PG), therefore, 
drug surface available for dissolution was tremendously increased 
compared to the marketed drug. Another explanation is to the 
possible increment in the Cs in the case of liquisolid system due to 
the presence of small quantities of PG that act as cosolvent with the 
aqueous dissolution medium of the stagnant diffusion layer, 
resulting in a larger drug concentration gradient (Cs _ C), thereby 
increasing the dissolution rate [30]. 
-C (concentration gradient where C 
is the drug concentration in the bulk of the dissolving medium, and 
finally Cs is the saturation solubility of the drug in the dissolution 
medium). 
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Table 5: In vitro disintegration and dissolution parameters for cefixime liquisolid capsules 
Formulas DT (min) % D45 min (%) 
F1 27±0.35 92.07±0.23 
F2 26±0.41 97.9±0.41 
F3 25±0.76 99.5±0.53 
F4 26±0.24 79.6±0.31 
F5 27±0.34 91.2±0.18 
F6 26±0.21 95.1±0.17 
F7 25±0.09 78.5±0.31 
F8 26±0.45 85.1±0.24 
F9 27±0.32 85.44±0.45 
*Abbreviations: Disintegration time (DT), % drug release after 45 min (% D45 min
 
). Results are expressed as mean±SD, n=3. 
 
Fig. 4: In vitro release profile for liquisolid formulas (F1-F3) 
containing 70% cefixime and with R-values (6, 8 and 10) 
respectively in phosphate buffer pH 7.2 (Results are expressed 
as mean±SD, n=3) 
 
 
Fig. 5: In vitro release profile for liquisolid formulas (F4-F6) 
containing 75% cefixime and with R-values (6,8 and 10) 
respectively in phosphate buffer pH 7.2 (Results are expressed 
as mean±SD, n=3) 
 
 
Fig. 6: In vitro release profile for liquisolid formulas (F7-F9) 
containing 80% cefixime and with R-values (6, 8 and 10) 
respectively in phosphate buffer pH 7.2 (Results are expressed 
as mean±SD, n=3) 
 
Fig. 7: In vitro release profile for optimum formula (F3) and 
cefixime marketed drug in phosphate buffer pH 7.2 (Results are 
expressed as mean±SD, n=3) 
 
CONCLUSION 
In this research, it is proved that liquisolid technology can be 
implemented to enhance the solubility and dissolution of cefixime 
trihydrate, which might significantly improve its absorption via the 
oral route leading to increase its bioavailability and might reduce its 
dose intake. 
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